Lepu Biopharma Co. Ltd. has announced the successful completion of the H Share full circulation, following the issuance of the Filing Notice by the China Securities Regulatory Commission (CSRC) and the subsequent grant of listing approval by the Hong Kong Stock Exchange. The conversion of 54,268,364 unlisted domestic shares into H shares was finalized on July 21, 2025, and the newly converted H shares will begin trading on the Stock Exchange at 9:00 a.m. on July 22, 2025. This development marks a significant milestone in the company's shareholding structure, with H shares now comprising 100% of the company's total share capital, enhancing liquidity and accessibility for investors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.